Literature DB >> 17531608

The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in peri-menopausal women.

Ian Milsom1.   

Abstract

INTRODUCTION: Hysterectomy is one of the most common surgical procedures performed in gynecological practice, and the most common indication for hysterectomy is menorrhagia or excessive menstrual bleeding. Approximately 10-15% of fertile women have menorrhagia, defined as a menstrual blood loss (MBL) of >80 mL. Since operative treatment in the form of a hysterectomy carries a not insignificant risk of morbidity and mortality, various forms of medical treatment have been advocated as initial treatment.
RESULTS: Antifibrinolytic agents, e.g., tranexamic acid (40-50% reduction), prostaglandin synthetase inhibitors (20-25% reduction), oral contraceptives (40-50%) and the intrauterine release of progestin with the levonorgestrel-releasing intrauterine system (LNG-IUS; 86-97% reduction), have all been shown to reduce MBL and to be effective in the treatment of idiopathic menorrhagia. In comparative and noncomparative trials, the greatest reduction in MBL has been achieved with the LNG-IUS. Thus, this system has been proposed as an alternative to hysterectomy in women with menorrhagia. In a randomized controlled trial, the LNG-IUS was compared with hysterectomy. Only 42% of the women randomized to the LNG-IUS system subsequently underwent a hysterectomy during the 5-year observation period, and the total costs (direct and indirect) were 40% lower with the LNG-IUS than with hysterectomy.
CONCLUSION: Despite the strong evidence that medical treatment and, in particular, the LNG-IUS are effective, many hysterectomies and endometrial ablations/resections are performed annually without first evaluating medical treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531608     DOI: 10.1016/j.contraception.2007.01.003

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

Review 1.  Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-11-01

Review 2.  Caring for the breast cancer survivor's health and well-being.

Authors:  Petra M Casey; Stephanie S Faubion; Kathy L MacLaughlin; Margaret E Long; Sandhya Pruthi
Journal:  World J Clin Oncol       Date:  2014-10-10

3.  Non-contraceptive applications of the levonorgestrel intrauterine system.

Authors:  Maria Isabel Rodriguez; Philip D Darney
Journal:  Int J Womens Health       Date:  2010-08-09

4.  The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability.

Authors:  Megan N Beatty; Paul D Blumenthal
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

5.  Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women.

Authors:  Rathnamala M Desai
Journal:  J Midlife Health       Date:  2012-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.